API
< Back to all clusters
[HEALTH] · India · 13 sources

started · updated

NPPA caps trade margins on 137 anti-cancer drugs in India

The National Pharmaceutical Pricing Authority (NPPA) has implemented a Trade Margin Rationalisation (TMR) measure to cap trade margins at 30% of the Maximum Retail Price (MRP) for 137 non-scheduled anti-cancer drugs. This regulatory intervention, under the Department of Pharmaceuticals, is expected to reduce the prices of these life-saving medicines by up to 70%, depending on their current price structures.

The decision follows recommendations from an expert committee under the Directorate General of Health Services (DGHS), which included oncologists and medical specialists. The move aims to curb excessive mark-ups in the distribution chain and alleviate the significant financial burden on cancer patients and their families. The list of drugs includes immunotherapy treatments, Denosumab, Pegfilgrastim, and Bevacizumab.

Revised prices are scheduled to take effect on November 9, 2026. Manufacturers are required to notify the NPPA of their revised prices within seven days of the Gazette notification and must display updated price lists on their websites. Retailers and hospitals are also mandated to display the new prices in pharmacies and on their digital platforms. Officials estimate the intervention could yield annual savings of approximately ₹2,500 crore.

Entities

Department of Pharmaceuticals · Directorate General of Health Services · India · Ministry of Chemicals and Fertilizers · National Pharmaceutical Pricing Authority

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

NPPA Caps Margins On 137 Cancer Drugs [www.deccanchronicle.com]